Bosutinib (SKI-606) | 1584

Bosutinib (SKI-606) is a novel tyrosine kinase inhibitor. Bosutinib can overcome not only Bcr-Abl-dependent mechanisms of resistance, but also those that are Bcr-Abl-independent. It is used to treat patients with chronic myelogenous leukemia (CML) who demonstrate resistance to Imatinib or develop resistance during treatment.

Bosutinib (SKI-606) is a novel tyrosine kinase inhibitor. Bosutinib can overcome not only Bcr-Abl-dependent mechanisms of resistance, but also those that are Bcr-Abl-independent.

1584 | Bosutinib (SKI-606) DataSheet

Alternate Name/Synonyms: SKI-606

Appearance: White to off-white solid

Formulation: N/A

CAS Number: 380843-75-4

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₆H₂₉Cl₂N₅O₃

Molecular Weight: 530.45

Cell-Permeable?: Yes

Purity: ≥99% by HPLC

Solubilities: DMSO (30 mg/ml) or EtOH (10 mg/ml)

Handling: Protect from light and moisture

Country of Origin: USA

Tag Line: A protein tyrosine kinase (PTK) inhibitor

MDL Number: MFCD07367846

PubChem CID: 46926609

SMILES: CN1CCN(CC1)CCCOC2=CC3=NC(=CC(=C3C=C2OC)NC4=CC(=C(C=C4Cl)Cl)OC)C#N

InChi: InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-26-14-22-18(12-25 (26)35-3)21(11-17(16-29)30-22)31-23-15-24(34-2)20(28)13-19(23)27/h11- 15H,4-10H2,1-3H3,(H,30,31)

InChi Key: ALUXPRDJABOEAG-UHFFFAOYSA-N